4//SEC Filing
Sofinnova Venture Partners X, L.P. 4
Accession 0000899243-20-020562
CIK 0001693011other
Filed
Jul 27, 8:00 PM ET
Accepted
Jul 28, 6:08 PM ET
Size
15.6 KB
Accession
0000899243-20-020562
Insider Transaction Report
Form 4
Sofinnova Management X, L.L.C.
10% Owner
Transactions
- Purchase
Common Stock
2020-07-28$16.00/sh+437,500$7,000,000→ 2,028,308 total - Conversion
Series A-2 Convertible Preferred Stock
2020-07-28−11,888,112→ 0 total→ Common Stock (1,590,808 underlying) - Conversion
Common Stock
2020-07-28+1,590,808→ 1,590,808 total
POWELL MICHAEL
10% Owner
Transactions
- Conversion
Common Stock
2020-07-28+1,590,808→ 1,590,808 total - Conversion
Series A-2 Convertible Preferred Stock
2020-07-28−11,888,112→ 0 total→ Common Stock (1,590,808 underlying) - Purchase
Common Stock
2020-07-28$16.00/sh+437,500$7,000,000→ 2,028,308 total
Sofinnova Venture Partners X, L.P.
10% Owner
Transactions
- Conversion
Common Stock
2020-07-28+1,590,808→ 1,590,808 total - Purchase
Common Stock
2020-07-28$16.00/sh+437,500$7,000,000→ 2,028,308 total - Conversion
Series A-2 Convertible Preferred Stock
2020-07-28−11,888,112→ 0 total→ Common Stock (1,590,808 underlying)
HEALY JAMES
10% Owner
Transactions
- Conversion
Common Stock
2020-07-28+1,590,808→ 1,590,808 total - Conversion
Series A-2 Convertible Preferred Stock
2020-07-28−11,888,112→ 0 total→ Common Stock (1,590,808 underlying) - Purchase
Common Stock
2020-07-28$16.00/sh+437,500$7,000,000→ 2,028,308 total
Katabi Maha
10% Owner
Transactions
- Purchase
Common Stock
2020-07-28$16.00/sh+437,500$7,000,000→ 2,028,308 total - Conversion
Common Stock
2020-07-28+1,590,808→ 1,590,808 total - Conversion
Series A-2 Convertible Preferred Stock
2020-07-28−11,888,112→ 0 total→ Common Stock (1,590,808 underlying)
Footnotes (2)
- [F1]On July 28, 2020, the Series A-2 Convertible Preferred Stock automatically converted into Common Stock on a 7.4730-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
- [F2]The shares are held directly by Sofinnova Venture Partners X, L.P. ("SVP X"). Sofinnova Management X, L.L.C. ("SM X") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy, Maha Katabi, and Michael F. Powell are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein.
Documents
Issuer
Inozyme Pharma, Inc.
CIK 0001693011
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001680200
Filing Metadata
- Form type
- 4
- Filed
- Jul 27, 8:00 PM ET
- Accepted
- Jul 28, 6:08 PM ET
- Size
- 15.6 KB